Assessing pharmacological interventions for bone metastases: the need for more patient-centered outcomes.

abstract：:Acetaminophen (APAP)/paracetamol is one of the most commonly used over-the-counter drugs taken worldwide for treatment of pain and fever. Although considered as safe when taken in recommended doses not higher than 4 g/day, APAP overdose is currently the most important cause of acute liver failure (ALF). ALF may requir...

journal_title：Expert review of clinical pharmacology

authors： Tiegs G,Karimi K,Brune K,Arck P

更新日期：2014-09-01 00:00:00

abstract：INTRODUCTION:In pediatric pharmacotherapy, many drugs are still used off-label, and their efficacy and safety is not well characterized. Different efficacy and safety profiles in children of varying ages may be anticipated, due to developmental changes occurring across pediatric life. AREAS COVERED:Beside pharmacokine...

journal_title：Expert review of clinical pharmacology

authors： Brussee JM,Calvier EA,Krekels EH,Välitalo PA,Tibboel D,Allegaert K,Knibbe CA

更新日期：2016-09-01 00:00:00

abstract：:In acute myocardial ischemia (AMI) the optimal treatment is rapid revascularization by angioplasty or pharmacological thrombolysis. While this is essential to resuscitate the ischemic myocardium, it results in further reperfusion injury and extension of the infarction. The main hypothesis for the mechanism of reperfus...

journal_title：Expert review of clinical pharmacology

authors： Qin C,Yap S,Woodman OL

更新日期：2009-11-01 00:00:00

abstract：:RNAi is a powerful gene silencing process that holds great promise in cancer therapy by the use of siRNA. The aim of this review is to give an outline on different approaches to deliver siRNA and to describe the advantages and disadvantages of these systems. The prospects for siRNA are to be substantially better than ...

journal_title：Expert review of clinical pharmacology

authors： Ali HM,Urbinati G,Raouane M,Massaad-Massade L

更新日期：2012-07-01 00:00:00

abstract：:Aripiprazole monohydrate (AM) and aripiprazole lauroxil (AL) are two different long-acting injectable formulations of aripiprazole. AM 400 mg administered once monthly demonstrated efficacy in an acute, double-blind, placebo-controlled, randomized clinical trial, as well as in a double-blind, placebo-controlled, rando...

journal_title：Expert review of clinical pharmacology

authors： Citrome L

更新日期：2016-01-01 00:00:00

abstract：INTRODUCTION:Osteoarthritis constitutes one of the leading causes of pain and disability worldwide with a significant impact on health-care costs. Patients with osteoarthritis are often affected by a number of cardiovascular comorbidities, including hypertension, which is present in about 40% of cases. Just recently, a...

journal_title：Expert review of clinical pharmacology

authors： Angeli F,Trapasso M,Signorotti S,Verdecchia P,Reboldi G

更新日期：2018-11-01 00:00:00

abstract：:Novel pharmaceutical advances in postoperative pain management include both non-opioid adjuvants as well as opioid analgesics. Optimizing postoperative analgesics includes improving onset of action, matching duration of analgesia to the setting of use, and minimizing adverse events. To improve on the current standard ...

journal_title：Expert review of clinical pharmacology

authors： Palmer P

更新日期：2015-01-01 00:00:00

abstract：INTRODUCTION:Gemtuzumab ozogamicin (GO) is an antibody-drug conjugate consisting of a monoclonal antibody targeting CD33 linked to a cytotoxic derivative of calicheamicin. Despite the known clinical efficacy in relapsed/refractory acute myeloid leukemia (AML), GO was withdrawn from the market in 2010 due to increased e...

journal_title：Expert review of clinical pharmacology

authors： Baron J,Wang ES

更新日期：2018-06-01 00:00:00

abstract：INTRODUCTION:Large-scale epidemiological studies on Greenlandic, Canadian and Alaskan Eskimos have examined the health benefits of omega-3 fatty acids consumed as part of the diet, and found statistically significant relative reduction in cardiovascular risk in people consuming omega-3 fatty acids. Areas covered: This ...

journal_title：Expert review of clinical pharmacology

authors： Watanabe Y,Tatsuno I

更新日期：2017-08-01 00:00:00

abstract：OBJECTIVES:To estimate the prevalence of polypharmacy (≥5 drugs) among adults and to analyze related factors. METHODS:Cross-sectional study with 1,159 interviewees distributed across 104 cities and 253 primary healthcare services delivered through the Brazilian Unified Health System. Polypharmacy-related factors were ...

journal_title：Expert review of clinical pharmacology

authors： Moreira T,Alvares-Teodoro J,Barbosa MM,Do Nascimento RCRM,Guerra Júnior AA,Acurcio FA

更新日期：2020-12-01 00:00:00

abstract：:Preeclampsia is a pregnancy-specific multisystem disorder, complicating 2 - 8% of pregnancies, and represents a leading cause of maternal and perinatal morbidity and mortality. Recent investigations have elucidated the understanding of its underlying pathogenic mechanisms. However, despite these advances, therapeutic ...

journal_title：Expert review of clinical pharmacology

authors： Ornaghi S,Paidas MJ

更新日期：2014-09-01 00:00:00

abstract：:Reducing the burden of falciparum malaria in pregnancy is an urgent international public health priority but one that involves considerable challenges. The rapidly declining effectiveness of agents known to be safe in pregnancy, and the limited efficacy, safety and pharmacokinetic data available for many other antimal...

journal_title：Expert review of clinical pharmacology

authors： Vallely A,McCarthy J,Changalucha J,Vallely L,Chandramohan D

更新日期：2008-01-01 00:00:00

abstract：INTRODUCTION:In the modern antimicrobial era, the rapid spread of resistance to antibiotics and introduction of new and mutating viruses is a global concern. Combating antimicrobial resistant microbes (AMR) requires coordinated international efforts that incorporate new conventional antibiotic development as well as de...

journal_title：Expert review of clinical pharmacology

authors： Enioutina EY,Teng L,Fateeva TV,Brown JCS,Job KM,Bortnikova VV,Krepkova LV,Gubarev MI,Sherwin CMT

更新日期：2017-11-01 00:00:00

abstract：:Introduction: Statins remain among the most frequently prescribed drugs and constitute a cornerstone in the prevention of cardiovascular disease. However, muscle symptoms are often reported from patients on statins. Muscle symptoms are frequently reported as adverse events associated with statin therapy.Areas covered:...

journal_title：Expert review of clinical pharmacology

authors： Pergolizzi JV Jr,Coluzzi F,Colucci RD,Olsson H,LeQuang JA,Al-Saadi J,Magnusson P

更新日期：2020-03-01 00:00:00

abstract：:Chronic diarrhea remains a common condition that affects people infected with human immunodeficiency virus (HIV) despite the widespread use of potent antiretroviral therapy. It is important that providers control this condition, as the persistence of diarrhea affects the quality of life of patients and may contribute ...

journal_title：Expert review of clinical pharmacology

authors： Castro JG,Chin-Beckford N

更新日期：2015-01-01 00:00:00

abstract：:Introduction: In September of 2018, the United States Federal Drug Administration (FDA) approved cemiplimab-rwlc (Libtayo) for advanced cutaneous squamous cell carcinoma (CSCC). Cemiplimab is an intravenous human monoclonal antibody directed against programmed cell death-1 receptor (PD-1). Cemiplimab blocks T-cell ina...

journal_title：Expert review of clinical pharmacology

authors： Ahmed SR,Petersen E,Patel R,Migden MR

更新日期：2019-10-01 00:00:00

abstract：INTRODUCTION:Acute bacterial skin and skin structure infections (ABSSSI) are among the most frequent infectious diseases. Recently, several new antibiotics with activity against MRSA have been approved. Tedizolid, a second-generation oxazolidinone approved for ABSSSI offers theoretical advantages over first-generation ...

journal_title：Expert review of clinical pharmacology

authors： Carena AA,Stryjewski ME

更新日期：2020-06-01 00:00:00

abstract：:Osteoarthritis is a progressive disease that affects millions of people worldwide, but for which there are no curative options and indeed a limited number of medical treatment options. The American College of Rheumatology recommendations suggest administering either a traditional NSAID or a COX-2-selective inhibitor f...

journal_title：Expert review of clinical pharmacology

authors： Sebba A

更新日期：2008-05-01 00:00:00

abstract：:Introduction: The clinical use of tacrolimus is characterized by many side effects which include neurotoxicity. In contrast, tacrolimus has also shown to have neuroregenerative properties. On a molecular level, the mechanisms of action could provide us more insight into understanding the neurobiological effects. The a...

journal_title：Expert review of clinical pharmacology

authors： Saffari TM,Bedar M,Zuidam JM,Shin AY,Baan CC,Hesselink DA,Hundepool CA

更新日期：2019-11-01 00:00:00

abstract：:Research on the specific effects of sex and gender on pharmacokinetics and pharmacodynamics, as well as safety profile tolerability and drug efficacy, of medications remain meager because female animals and women have only recently been included in the pharmacological domain. To date, the influence of sex and gender o...

journal_title：Expert review of clinical pharmacology

authors： Franconi F,Campesi I

更新日期：2014-07-01 00:00:00

abstract：:Introduction: The development of immunotherapies and targeted therapies has changed the treatment approach in resectable, nonresectable, and metastatic melanoma. Because of their different pharmacological profiles, immunotherapies and/or targeted therapies have been studied in various combinations.Areas covered: We re...

journal_title：Expert review of clinical pharmacology

authors： Krattinger R,Ramelyte E,Dornbierer J,Dummer R

更新日期：2020-03-19 00:00:00

abstract：INTRODUCTION:Allogeneic hematopoietic cell transplants (allo-HCT) recipients are at the high-risk of reactivation of cytomegalovirus (CMV), and reactivation is associated with significant morbidity and mortality. Although available anti-CMV therapies may be effective for the prevention of CMV, they are plagued by unacc...

journal_title：Expert review of clinical pharmacology

authors： Foolad F,Aitken SL,Chemaly RF

更新日期：2018-10-01 00:00:00

abstract：:Sugammadex, a modified γ-cyclodextrin, is the first selective relaxant binding agent. Sugammadex forms very tight complexes in a 1:1 ratio with steroidal neuromuscular blocking agents (rocuronium > vecuronium > pancuronium). This guest-host complex, which exists in equilibrium, is stable because of its very high assoc...

journal_title：Expert review of clinical pharmacology

authors： Naguib M,Brull SJ

更新日期：2009-01-01 00:00:00

abstract：INTRODUCTION:Bacterial resistance to antibiotics is increasing worldwide, due to the emergence of multidrug-resistant strains. With this panorama, there is a serious danger that we may be entering the 'post-antibiotic era'. Areas covered: We assess why so few new classes of antibiotics have been developed in the past y...

journal_title：Expert review of clinical pharmacology

authors： Rello J,Bunsow E,Perez A

更新日期：2016-12-01 00:00:00

abstract：INTRODUCTION:The immune system can restrain or promote cancer development and growth. Antibodies targeting immune checkpoints have revolutionized cancer treatment. Among the best responses have been in non-small cell lung cancer (NSCLC) which is largely caused by chronic exposure to carcinogens; associated with high ne...

journal_title：Expert review of clinical pharmacology

authors： Santini FC,Rudin CM

更新日期：2017-09-01 00:00:00

abstract：INTRODUCTION:Betalactams are the most widely used drugs against infections and the primary cause of antibiotic hypersensitivity reactions. Reaction patterns for different betalactams have been changing in accordance with consumption trends, and vary among countries. As a consequence, in vivo and in vitro tests have had...

journal_title：Expert review of clinical pharmacology

authors： Fernandez TD,Mayorga C,Salas M,Barrionuevo E,Posadas T,Ariza A,Laguna JJ,Moreno E,Torres MJ,Doña I,Montañez MI

更新日期：2017-06-01 00:00:00

abstract：:Introduction: Patients with early HER2-positive breast cancer (BC) benefit from HER2-targeted systemic therapy. The endorsed standard adjuvant treatment for patients with early HER2-positive breast cancer is chemotherapy plus trastuzumab administered for 1 year. Areas covered: Several trials have investigated modifica...

journal_title：Expert review of clinical pharmacology

authors： Esposito A,Viale G,Criscitiello C,Curigliano G

更新日期：2019-01-01 00:00:00

abstract：:'IDegLira' combines insulin degludec (IDeg) with the glucagon-like peptide-1 analog liraglutide (Lira) at a ratio of 1 unit IDeg to 0.036 mg Lira. The two components have complementary therapeutic actions for the treatment of Type 2 diabetes. Studies have shown that combinations of basal insulin with glucagon-like pep...

journal_title：Expert review of clinical pharmacology

authors： Simpson R,King A

更新日期：2015-03-01 00:00:00

abstract：INTRODUCTION:Gaucher disease (GD) is an autosomal recessive disorder resulting from the deficiency of the lysosomal enzyme glucocerebrosidase (b-glucosidase), associated with varying degrees of visceral, bone and central nervous system pathology, leading to wide phenotypic diversity. Response to therapy and clinical ou...

journal_title：Expert review of clinical pharmacology

authors： Gupta P,Pastores G

更新日期：2018-12-01 00:00:00

abstract：:Rosacea is a chronic inflammatory dermatologic condition that can often be disfiguring with significant negative impact on patients' quality of life. Sanrosa (brimonidine tartate) is a novel therapeutic agent targeting the facial flushing and erythema of rosacea through its α₂ adrenergic receptor agonist activity. The...

journal_title：Expert review of clinical pharmacology

authors： Tong LX,Moore AY

更新日期：2014-09-01 00:00:00